September 19, 2020

The Niche

Knoepfler lab stem cell blog

Ocata

3 min read

Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, which looks to be a dramatic year in the field of stem cells and regenerative medicine. The Score Card on 2016 Predictions Another stem cell biotech acquisition by pharma …Read More

4 min read

The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to polls, has been the leading backer of the REGROW Act. Kirk has been more in the news of late due to extremely controversial Trump-like comments he made about his …Read More

2 min read

What will the new year have in store for stem cells? 2016 promises to have many striking stem cell developments. Below are my top 20 stem cell predictions for what is to come this year in no particular order. Share your stem cell tea leaves in the comments please. Another stem cell biotech acquisition by pharma (recall Ocata (almost now finally sold) & CDI in 2015). Charging patients for clinical trial participation, particularly in Japan due to the new policy and here in the US …Read More

2 min read

Money plays a major role in the arena of stem cells, cell therapy, and regenerative medicine. The financial side of this cutting-edge field ranges from grants to private investors to publicly traded stocks. One could argue that the flow of total investment going into this area has a direct and tangible impact on how rapidly and effectively the research moves forward. In the specific area of publicly traded companies working in stem cells, cell therapy, and regenerative medicine, what’s the investment outlook for the coming …Read More